Cholesterol-lowering action of BNA-based antisense oligonucleotides targeting PCSK9 in atherogenic diet-induced hypercholesterolemic mice

Molecular Therapy Nucleic Acids

Volumn 1, Issue 5, 2012, Pages e22-

  Yamamoto, Tsuyoshi ^a,b   Harada Shiba, Mariko ^b   Nakatani, Moeka ^a,b   Wada, Shunsuke ^b,c   Yasuhara, Hidenori ^a,b   Narukawa, Keisuke ^a   Sasaki, Kiyomi ^c   Shibata, Masa Aki ^d   Torigoe, Hidetaka ^c   Yamaoka, Tetsuji ^b   Imanishi, Takeshi ^e   Obika, Satoshi ^a  

^a OSAKA UNIVERSITY   (Japan)

^b NATIONAL CEREBRAL AND CARDIOVASCULAR CENTER   (Japan)

^c TOKYO UNIVERSITY OF SCIENCE   (Japan)

^d OSAKA HEALTH SCIENCE UNIVERSITY   (Japan)

^e BNA Inc   (Japan)

Author keywords

Antisense; BNA; Hypercholesterolemia; LNA; PCSK9

Indexed keywords

EID: 84868359439     PISSN: None     EISSN: 21622531     Source Type: Journal    
DOI: 10.1038/mtna.2012.16     Document Type: Article

References (42)

1. Jones, P, Kafonek, S, Laurora, I and Hunninghake, D (1998). Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study). Am J Cardiol 81: 582-587. (Pubitemid 28182422)
2. Goldstein, JL and Brown, MS (2009). The LDL receptor. Arterioscler Thromb Vasc Biol 29: 431-438.
3. Horton, JD, Goldstein, JL and Brown, MS (2002). SREBPs: activators of the complete program of cholesterol and fatty acid synthesis in the liver. J Clin Invest 109: 1125-1131. (Pubitemid 34496588)
4. Horton, JD, Shah, NA, Warrington, JA, Anderson, NN, Park, SW, Brown, MS et al. (2003). Combined analysis of oligonucleotide microarray data from transgenic and knockout mice identifies direct SREBP target genes. Proc Natl Acad Sci USA 100: 12027-12032. (Pubitemid 37271509)
5. Kong, WJ, Liu, J and Jiang, JD (2006). Human low-density lipoprotein receptor gene and its regulation. J Mol Med 84: 29-36. (Pubitemid 43099521)
6. Issandou, M (2006). Pharmacological regulation of low density lipoprotein receptor expression: current status and future developments. Pharmacol Ther 111: 424-433. (Pubitemid 43842071)
7. Zelcer, N and Tontonoz, P (2006). Liver X receptors as integrators of metabolic and inflammatory signaling. J Clin Invest 116: 607-614. (Pubitemid 43326865)
8. Garcia, CK, Wilund, K, Arca, M, Zuliani, G, Fellin, R, Maioli, M et al. (2001). Autosomal recessive hypercholesterolemia caused by mutations in a putative LDL receptor adaptor protein. Science 292: 1394-1398. (Pubitemid 32476229)
9. Harada-Shiba, M, Takagi, A, Miyamoto, Y, Tsushima, M, Ikeda, Y, Yokoyama, S et al. (2003). Clinical features and genetic analysis of autosomal recessive hypercholesterolemia. J Clin Endocrinol Metab 88: 2541-2547. (Pubitemid 36724420)
10. Abifadel, M, Varret, M, Rabès, JP, Allard, D, Ouguerram, K, Devillers, M et al. (2003). Mutations in PCSK9 cause autosomal dominant hypercholesterolemia. Nat Genet 34: 154-156. (Pubitemid 36666925)
11. Zelcer, N, Hong, C, Boyadjian, R and Tontonoz, P (2009). LXR regulates cholesterol uptake through Idol-dependent ubiquitination of the LDL receptor. Science 325: 100-104.
12. Lambert, G, Charlton, F, Rye, KA and Piper, DE (2009). Molecular basis of PCSK9 function. Atherosclerosis 203: 1-7.
13. Maxwell, KN, Soccio, RE, Duncan, EM, Sehayek, E and Breslow, JL (2003). Novel putative SREBP and LXR target genes identified by microarray analysis in liver of cholesterol-fed mice. J Lipid Res 44: 2109-2119. (Pubitemid 37509626)
14. Attie, AD and Seidah, NG (2005). Dual regulation of the LDL receptor-some clarity and new questions. Cell Metab 1: 290-292. (Pubitemid 43960618)
15. Cameron, J, Ranheim, T, Kulseth, MA, Leren, TP and Berge, KE (2008). Berberine decreases PCSK9 expression in HepG2 cells. Atherosclerosis 201: 266-273.
16. Kong, W, Wei, J, Abidi, P, Lin, M, Inaba, S, Li, C et al. (2004). Berberine is a novel cholesterol- lowering drug working through a unique mechanism distinct from statins. Nat Med 10: 1344-1351. (Pubitemid 40022716)
17. Kong, WJ, Wei, J, Zuo, ZY, Wang, YM, Song, DQ, You, XF et al. (2008). Combination of simvastatin with berberine improves the lipid-lowering efficacy. Metab Clin Exp 57: 1029-1037. (Pubitemid 351978060)
18. Chan, JC, Piper, DE, Cao, Q, Liu, D, King, C, Wang, W et al. (2009). A proprotein convertase subtilisin/kexin type 9 neutralizing antibody reduces serum cholesterol in mice and nonhuman primates. Proc Natl Acad Sci USA 106: 9820-9825.
19. Frank-Kamenetsky, M, Grefhorst, A, Anderson, NN, Racie, TS, Bramlage, B, Akinc, A et al. (2008). Therapeutic RNAi targeting PCSK9 acutely lowers plasma cholesterol in rodents and LDL cholesterol in nonhuman primates. Proc Natl Acad Sci USA 105: 11915-11920.
20. Gupta, N, Fisker, N, Asselin, MC, Lindholm, M, Rosenbohm, C, Ørum, H et al. (2010). A locked nucleic acid antisense oligonucleotide (LNA) silences PCSK9 and enhances LDLR expression in vitro and in vivo. PLoS ONE 5: e10682.
21. Swayze, EE, Siwkowski, AM, Wancewicz, EV, Migawa, MT, Wyrzykiewicz, TK, Hung, G et al. (2007). Antisense oligonucleotides containing locked nucleic acid improve potency but cause significant hepatotoxicity in animals. Nucleic Acids Res 35: 687-700. (Pubitemid 46232083)
22. Yamamoto, T, Nakatani, M, Narukawa, K and Obika, S (2011). Antisense drug discovery and development. Future Med Chem 3: 339-365.
23. Rahman, SM, Seki, S, Obika, S, Yoshikawa, H, Miyashita, K and Imanishi, T (2008). Design, synthesis, and properties of 2',4'-BNA(NC): a bridged nucleic acid analogue. J Am Chem Soc 130: 4886-4896. (Pubitemid 351500122)
24. Obika, S, Rahman, SMA, Fujisaka, A, Kawada, Y, Baba, T and Imanishi, T (2010). Bridged nucleic acids: development, synthesis, and properties. Heterocycles 81: 1347-1392.
25. Miyashita, K, Rahman, SMA, Seki, S, Obika, S and Imanishi, T (2007). N-Methyl substituted 2',4'-BNA(NC): a highly nuclease-resistant nucleic acid analogue with high-affinity RNA selective hybridization. Chem Commun: 3765-3767. (Pubitemid 47404177)
26. Prakash, TP, Siwkowski, A, Allerson, CR, Migawa, MT, Lee, S, Gaus, HJ et al. (2010). Antisense oligonucleotides containing conformationally constrained 2',4'-(N-methoxy) aminomethylene and 2',4'-aminooxymethylene and 2'-O,4'-C-aminomethylene bridged nucleoside analogues show improved potency in animal models. J Med Chem 53: 1636-1650.
27. Graham, MJ, Lemonidis, KM, Whipple, CP, Subramaniam, A, Monia, BP, Crooke, ST et al. (2007). Antisense inhibition of proprotein convertase subtilisin/kexin type 9 reduces serum LDL in hyperlipidemic mice. J Lipid Res 48: 763-767. (Pubitemid 46557881)
28. Yu, RZ, Baker, B, Chappell, A, Geary, RS, Cheung, E and Levin, AA (2002). Development of an ultrasensitive noncompetitive hybridization-ligation enzyme-linked immunosorbent assay for the determination of phosphorothioate oligodeoxynucleotide in plasma. Anal Biochem 304: 19-25. (Pubitemid 34492838)
29. Straarup, EM, Fisker, N, Hedtjärn, M, Lindholm, MW, Rosenbohm, C, Aarup, V et al. (2010). Short locked nucleic acid antisense oligonucleotides potently reduce apolipoprotein B mRNA and serum cholesterol in mice and non-human primates. Nucleic Acids Res 38: 7100-7111.
30. Agrawal, S, Temsamani, J and Tang, JY (1991). Pharmacokinetics, biodistribution, and stability of oligodeoxynucleotide phosphorothioates in mice. Proc Natl Acad Sci USA 88: 7595-7599. (Pubitemid 21915200)
31. Phillips, JA, Craig, SJ, Bayley, D, Christian, RA, Geary, R and Nicklin, PL (1997). Pharmacokinetics, metabolism, and elimination of a 20-mer phosphorothioate oligodeoxynucleotide (CGP 69846A) after intravenous and subcutaneous administration. Biochem Pharmacol 54: 657-668. (Pubitemid 27404625)
32. Lendvai, G, Velikyan, I, Bergström, M, Estrada, S, Laryea, D, Välilä, M et al. (2005). Biodistribution of 68Ga-labelled phosphodiester, phosphorothioate, and 2'-O-methyl phosphodiester oligonucleotides in normal rats. Eur J Pharm Sci 26: 26-38. (Pubitemid 41097258)
33. Akdim, F, Visser, ME, Tribble, DL, Baker, BF, Stroes, ES, Yu, R et al. (2010). Effect of mipomersen, an apolipoprotein B synthesis inhibitor, on low-density lipoprotein cholesterol in patients with familial hypercholesterolemia. Am J Cardiol 105: 1413-1419.
34. Akdim, F, Stroes, ES, Sijbrands, EJ, Tribble, DL, Trip, MD, Jukema, JW et al. (2010). Efficacy and safety of mipomersen, an antisense inhibitor of apolipoprotein B, in hypercholesterolemic subjects receiving stable statin therapy. J Am Coll Cardiol 55: 1611-1618.
35. Heemskerk, H, de Winter, C, van Kuik, P, Heuvelmans, N, Sabatelli, P, Rimessi, P et al. (2010). Preclinical PK and PD studies on 2'-O-methyl- phosphorothioate RNA antisense oligonucleotides in the mdx mouse model. Mol Ther 18: 1210-1217.
36. Rudling, M (1992). Hepatic mRNA levels for the LDL receptor and HMG-CoA reductase show coordinate regulation in vivo. J Lipid Res 33: 493-501.
37. Dueland, S, Drisko, J, Graf, L, Machleder, D, Lusis, AJ and Davis, RA (1993). Effect of dietary cholesterol and taurocholate on cholesterol 7 alpha-hydroxylase and hepatic LDL receptors in inbred mice. J Lipid Res 34: 923-931. (Pubitemid 23182691)
38. Thomas, C, Pellicciari, R, Pruzanski, M, Auwerx, J and Schoonjans, K (2008). Targeting bile-acid signalling for metabolic diseases. Nat Rev Drug Discov 7: 678-693.
39. Chiang, JY (2009). Bile acids: regulation of synthesis. J Lipid Res 50: 1955-1966.
40. Pullinger, CR, Eng, C, Salen, G, Shefer, S, Batta, AK, Erickson, SK et al. (2002). Human cholesterol 7alpha-hydroxylase (CYP7A1) deficiency has a hypercholesterolemic phenotype. J Clin Invest 110: 109-117. (Pubitemid 34743471)
41. Machleder, D, Ivandic, B, Welch, C, Castellani, L, Reue, K and Lusis, AJ (1997). Complex genetic control of HDL levels in mice in response to an atherogenic diet. Coordinate regulation of HDL levels and bile acid metabolism. J Clin Invest 99: 1406-1419. (Pubitemid 27142779)
42. Miyake, JH, Duong-Polk, XT, Taylor, JM, Du, EZ, Castellani, LW, Lusis, AJ et al. (2002). Transgenic expression of cholesterol-7-alpha-hydroxylase prevents atherosclerosis in C57BL/6J mice. Arterioscler Thromb Vasc Biol 22: 121-126. (Pubitemid 34076242)